Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;104(12):2358-2360.
doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Philippe Moreau  1 , Pieter Sonneveld  2 , Mario Boccadoro  3 , Gordon Cook  4 , Ma Victoria Mateos  5 , Hareth Nahi  6 , Hartmut Goldschmidt  7 , Meletios A Dimopoulos  8 , Paulo Lucio  9 , Joan Bladé  10 , Michel Delforge  11 , Roman Hajek  12 , Heinz Ludwig  13 , Thierry Facon  14 , Jesus F San Miguel  15 , Hermann Einsele  16
Affiliations

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Philippe Moreau et al. Haematologica. 2019 Dec.

Abstract

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.

PubMed Disclaimer

Comment in

  • Teaming up for CAR-T cell therapy.
    Wäsch R, Munder M, Marks R. Wäsch R, et al. Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676. Haematologica. 2019. PMID: 31787616 Free PMC article. No abstract available.

References

    1. Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660. - PMC - PubMed
    1. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130(24):2594–2602. - PMC - PubMed
    1. Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019;9:146. - PMC - PubMed
    1. Laâbi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 1992;11(11):3897–3904. - PMC - PubMed
    1. Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Anti-BCMA antibodies in the future management of multiple myeloma. Expert Rev Anticancer Ther. 2019;19(4):319–326. - PubMed